Sera Prognostics (SERA) Net Margin (2020 - 2026)
Sera Prognostics (SERA) posted Net Margin of 77557.14% for Q1 2026, down 55.24% on a QoQ basis from 49960.0% in Q4 2025, and down 5520188.0% year-over-year from N/an in Q1 2025.
Sera Prognostics (SERA) Net Margin (2020 - 2026) Analysis & Trends
Sera Prognostics' Net Margin history runs 7 years deep, the most recent figure standing at 77557.14% for Q1 2026.
- Quarterly Net Margin fell 5520188.0% year-over-year to 77557.14% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71733.33% (down 4138203.0% YoY) and the FY2025 annual result came in at 145618.52%, down 17956.0% from the prior year.
- Net Margin was 77557.14% for Q1 2026 at Sera Prognostics, down from 49960.0% in the prior quarter.
- Across five years, Net Margin topped out at 9328.46% in Q2 2023 and bottomed at 79081.25% in Q3 2025.
- A 5-year average of 33777.26% and a median of 25472.46% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin soared 3221000 bps — and 2026, when it plunged 5520188 bps.
- Sera Prognostics' Net Margin stood at 16055.38% in 2022, then decreased by 14 bps to 18304.88% in 2023, then plunged by 113 bps to 39058.33% in 2024, then retreated by 28 bps to 49960.0% in 2025, then slumped by 55 bps to 77557.14% in 2026.
- Business Quant data shows SERA's Net Margin at 77557.14% in Q1 2026, 49960.0% in Q4 2025, and 79081.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 16.74% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.01% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Sera Prognostics | 109.06 Mn | 109.06 Mn | -28,000.00 | -77,557.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77,557.14% |
| Dec 31, 2025 | -49,960.00% |
| Sep 30, 2025 | -79,081.25% |
| Jun 30, 2025 | -72,829.41% |
| Mar 31, 2025 | -22,355.26% |
| Dec 31, 2024 | -39,058.33% |
| Sep 30, 2024 | -28,589.66% |
| Jun 30, 2024 | -36,433.33% |
| Dec 31, 2023 | -18,304.88% |
| Sep 30, 2023 | -18,635.71% |
| Jun 30, 2023 | -9,328.46% |
| Mar 31, 2023 | -11,345.00% |
| Dec 31, 2022 | -16,055.38% |
| Sep 30, 2022 | -12,883.91% |
| Jun 30, 2022 | -15,252.56% |
| Mar 31, 2022 | -32,765.79% |
| Dec 31, 2021 | -48,265.38% |
| Sep 30, 2021 | -42,960.87% |
| Jun 30, 2021 | -36,805.00% |
| Mar 31, 2021 | -56,169.23% |